Increased cerebral CO 2 reactivity after heparin-mediated extracorporal LDL precipitation (HELP) in patients with coronary heart disease and hyperlipidemia

Stroke

Volumn 30, Issue 9, 1999, Pages 1802-1806

  Pfefferkorn, Thomas K ^a   Knüppel, Hans Peter ^a   Jaeger, Beate R ^a   Thiery, Joachim ^a   Hamann, Gerhard F ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cerebrovascular reactivity; Endothelium; Hypercholesterolemia; Lipoproteins, LDL; Ultrasonography

Indexed keywords

FIBRINOGEN; HEPARIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL REACTIVITY; BLOOD VISCOSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; EXTRACORPOREAL CIRCULATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MALE; MIDDLE CEREBRAL ARTERY; PRECIPITATION; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; STROKE; VASCULAR ENDOTHELIUM;

EID: 0345493873     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.9.1802     Document Type: Article

References (25)

1. Lipid Research Clinics Program. The lipid research coronary primary prevention trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251: 365-374.
2. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Nikkilä EA. Helsinki Heart Study. Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
3. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphil L. Beneficial effects of combined colestopil-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987; 257:3233-3240.
4. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moue LA, Piller LB, Rutherford J, Simpson LM, Braunwald E, for the CARE Investigators. Reduction of stroke incidents after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. Circulation. 1999;99:216-223.
5. Blauw GJ, Lagaay M, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke. 1997;28:946-950.
6. Seidel D, Armstrong V, Schuff-Werner P, for the HELP Study Group. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease, I: evaluation of safety and cholesterol-lowering effects during the first 12 months. Eur J Clin Invest. 1991;21:375-383.
7. Wilhelmsen L, Svärsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen is a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
8. Kannel WB, Wolf PA, Castelli WP, D'Agostini RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258:1183-1186.
9. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brian JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 1991;83:836-844.
10. Schuff-Werner P, Schuetz E, Seyde W, Eisenhauer T, Janning G, Armstrong V, Seidel D. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extra-corporal LDL precipitation (HELP). Eur J Clin Invest. 1998;19:30-37.
11. Thiery J, Seidel D. Safety and effectiveness of long-term LDL-apheresis in patients at high risk. Curr Opin Lipidol. 1998;9:521-526.
12. Mathew V, Cannan C, Miller V, Barber A, Hasdai D, Schwarz R, Holmes D, Lerman A. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation. 1997;96:1930-1936.
13. Andrews H, Bruckdorfer K, Dunn R, Jacobs M. Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature. 1987;327: 237-239.
14. Kugiyama K, Kerns S, Morrisett J, Roberts R, Hzenry P. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 1990;244:160-162.
15. Galle J, Mülsch A, Busse R, Bassenge E. Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium derived relaxing factor. Arteriosclerosis. 1991;11:198-203.
16. Stadler RW, Ibrahim SF, Lees RS. Peripheral vasoactivity in familial hypercholesterolemic subjects treated with heparin-induced extracorporal LDL-precipitation (HELP). Atherosclerosis. 1997;128:241-249.
17. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation. 1997;95:76-82.
18. Mellwig KP, Baller D, Gleichmann U, Moll D, Betker S, Weise R, Notohamiprodjo G. Improvement of coronary vasodilatation capacity through single LDL-apheresis. Atherosclerosis. 1998;139:173-178.
19. Aalkjoer C, Poston L. Effects of pH on vascular tension: which are the important mechanisms? J Vasc Res. 1996;33:347-359.
20. Huber P, Handa J. Effect of contrast material, hypercapnia, hyperventilation, hypertonic glucose and papaverine on the diameter of the cerebral arteries: angiographic determination in man. J Invest Radiol. 1967;2:17-32.
21. 2 -induced cerebral vasomotor response in normal individuals and patients with internal carotid artery occlusions. Stroke. 1988;19: 963-969.
22. Eisenhauer T, Armstrong V, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr. 1987; 65:161-168.
23. Schuff-Werner, Gohlke H, Bartmann U, Baggio G, Corti M, Dinsenbacher A, Eisenhauer T, Grützmacher P, Keller C, Kettner U, Kleophas W, Köster W, Olbricht C, Richter W, Seidel D, and the HELP-study group. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest. 1994;24:724-732.
24. 2 reactivity during hypocapnia in normal subjects. Stroke. 1996;27:1328-1332.
25. Hein TW, Kuo L. LDLs impair vasomotor function of the coronary microcirculation: role of superoxide anions. Circ Res. 1998;83:404-414.